UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Menopause hormone therapy significantly alters pathophysiological biomarkers of Alzheimer's disease

Depypere, Herman; Vergallo, Andrea; Lemercier, Pablo; Lista, Simone; Benedet, Andrea; Ashton, Nicholas; Cavedo, Enrica; ... Neurodegeneration Precision Medicine Initiative (NPMI), (NPMI); + view all (2023) Menopause hormone therapy significantly alters pathophysiological biomarkers of Alzheimer's disease. Alzheimer's & Dementia , 19 (4) pp. 1320-1330. 10.1002/alz.12759. Green open access

[thumbnail of Menopause hormone therapy significantly alters pathophysiological biomarkers.pdf]
Preview
Text
Menopause hormone therapy significantly alters pathophysiological biomarkers.pdf - Published Version

Download (647kB) | Preview

Abstract

INTRODUCTION: This increasing body of literature indicates that menopause hormonal replacement therapy (MHT) may substantially mitigate the risk of developing late-life cognitive decline due to progressive Alzheimer's disease (AD) pathophysiology. For the first time, we investigated the question whether MHT impacts AD biomarker-informed pathophysiological dynamics in de-novo diagnosed menopausal women. METHODS: We analyzed baseline and longitudinal differences between MHT-taking and -not women in terms of concentrations of core pathophysiological AD plasma biomarkers, validated in symptomatic and cognitively healthy individuals, including biomarkers of (1) the amyloid-β (Aβ) pathway, (2) tau pathophysiology, (3) neuronal loss, and (4) axonal damage and neurodegeneration. RESULTS: We report a prominent and significant treatment response at the Aβ pathway biomarker level. Women at genetic risk for AD (APOE e4 allele carriers) have particularly shown favorable results from treatment. DISCUSSION: To our knowledge, we present first prospective clinical evidence on effects of MHT on AD pathophysiology during menopause.

Type: Article
Title: Menopause hormone therapy significantly alters pathophysiological biomarkers of Alzheimer's disease
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1002/alz.12759
Publisher version: https://doi.org/10.1002/alz.12759
Language: English
Additional information: © 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Neurodegeneration Precision Medicine Initiative (NPMI)
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases
URI: https://discovery.ucl.ac.uk/id/eprint/10159421
Downloads since deposit
68Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item